Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 2/20 | 0.55 |
| ▸ | HTR1B | P28222 | 4/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HTR1D | P28221 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.47 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.47 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15772640 | 0.97 | KCNA3 (0.54) | KCNA3HTR1BHTR1DMCHR1SLC6A4 | |
| SCHEMBL29447160 | 0.97 | KCNA3 (0.54) | KCNA3HTR1BHTR1DMCHR1SLC6A4 | |
| SCHEMBL15772317 | 0.90 | KCNA3 (0.50) | KCNA3HTR1BHTR1DMCHR1SLC6A4 | |
| SCHEMBL2098201 | 0.88 | TSHR (0.49) | KCNA3TSHRMCHR1GPBAR1CYSLTR2 | |
| SCHEMBL12967944 | 0.88 | CYP2D6 (0.54) | KCNA3HTR1BHTR1DMCHR1SLC6A4 | |
| SCHEMBL15772818 | 0.88 | MAPK1 (0.46) | KCNA3HTR1BSLC6A4CYP2C9CYP1A2 | |
| SCHEMBL249940 | 0.85 | CNR1 (0.48) | KCNA3HTR1BCYP2C9CNR1CNR2 | |
| SCHEMBL249138 | 0.85 | MTNR1A (0.50) | — | |
| SCHEMBL9421991 | 0.84 | KCNA3 (0.54) | KCNA3HTR1BHTR1DMCHR1SLC6A4 | |
| SCHEMBL10604096 | 0.84 | KCNA3 (0.54) | KCNA3HTR1BHTR1DMCHR1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1339663-B1 | NAPHTHALENE DERIVATIVES | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| EP-2338886-A2 | Naphthalene derivatives | Novartis AG (CH) | 2011-06-29 | — | — | EP | disclosed |
| US-7045533-B2 | Such as naphthalen-1-yl-(4-pentyloxy-naphthalen-1-yl)-mehtane for treatment/prevention of diseases/conditions associated with cannobinoid receptor activation such as chronic pain, osteo- and rheumatoid arthritis, teno-synovitis and gout | NOVARTIS AG (CH) | 2006-05-16 | — | — | US | disclosed |
| US-20040053890-A1 | Naphthalene derivatives | NOVARTIS AG (CH) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053890-A1 | Naphthalene derivatives | CYP1A1, SULT1E1, CYP2F1 | KCNA3 874/4885HTR1B 914/4885TSHR 2664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.